VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 75 filers reported holding VIRIDIAN THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,179,171 | -39.6% | 1,380,650 | -6.3% | 0.01% | -35.3% |
| Q2 2023 | $35,049,522 | +224260.0% | 1,473,288 | +139.9% | 0.02% | +88.9% |
| Q1 2023 | $15,622 | -39.0% | 614,089 | -29.9% | 0.01% | -35.7% |
| Q4 2022 | $25,596 | -99.8% | 876,254 | +15.0% | 0.01% | +55.6% |
| Q3 2022 | $15,630,000 | +20.0% | 762,060 | -32.3% | 0.01% | +12.5% |
| Q2 2022 | $13,029,000 | -27.8% | 1,126,085 | +15.4% | 0.01% | -20.0% |
| Q1 2022 | $18,039,000 | +97.3% | 975,618 | +111.0% | 0.01% | +100.0% |
| Q4 2021 | $9,141,000 | +244.4% | 462,390 | +186.6% | 0.01% | +150.0% |
| Q3 2021 | $2,654,000 | +23.3% | 161,345 | +37.1% | 0.00% | +100.0% |
| Q2 2021 | $2,153,000 | +198.6% | 117,715 | +172.6% | 0.00% | 0.0% |
| Q1 2021 | $721,000 | – | 43,176 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,699,865 | $78,863,057 | 13.28% |
| COMMODORE CAPITAL LP | 2,020,166 | $59,009 | 8.89% |
| ACUTA CAPITAL PARTNERS, LLC | 396,500 | $11,581,765 | 7.13% |
| Fairmount Funds Management LLC | 1,369,623 | $40,006,688 | 6.35% |
| Paradigm Biocapital Advisors LP | 1,751,167 | $51,151,588 | 6.00% |
| Vivo Capital, LLC | 1,678,207 | $49,020 | 5.64% |
| TCG Crossover Management, LLC | 983,610 | $28,731,248 | 5.07% |
| Kynam Capital Management, LP | 1,034,697 | $30,223,499 | 4.64% |
| Octagon Capital Advisors LP | 824,200 | $24,074,882 | 3.75% |
| Logos Global Management LP | 1,000,000 | $29,210,000 | 3.42% |